Learning Amyloid and Tau Results

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

240 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-02-28

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to identify factors that moderate and mediate these outcomes. Participants enrolled in this study are requested to complete surveys at four timepoints after learning their Alzheimer's biomarker test results.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Disclosing Dementia Risk Based on Plasma Phosphorylated Tau

NCT05377060

Alzheimer Disease Mild Cognitive Impairment

COMPLETED NA

Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)

NCT03022968

Alzheimer Disease Benson's Disease

COMPLETED PHASE2

Risk Evaluation and Education for Alzheimer's Disease

NCT00571025

Alzheimer's Disease

COMPLETED NA

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

NCT05584241

Mild Cognitive Impairment Alzheimer Disease Amnestic Mild Cognitive Disorder

ACTIVE_NOT_RECRUITING NA

Cognitive Assessment of Elderly Primary Care Patients

NCT01492335

Mild Cognitive Impairment

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The overall objective is to determine how learning one's amyloid and tau test results impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and identify factors that moderate and mediate these outcomes.

The rationale is that by understanding factors that explain variability in reactions, biomarker communication and post-testing support can be tailored to optimize outcomes.

The central hypothesis is that learning biomarker profile will affect psychosocial, behavioral, and neuropsychological outcomes, and that these outcomes will be moderated by social determinants of health (SDOH) and perceived communication factors and mediated by illness perceptions and beliefs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants from UW Alzheimer's Disease Research

Participants aged 50-89 who are cognitively unimpaired or have mild cognitive impairment will be enrolled from the Wisconsin Registry for Alzheimer's Prevention, Wisconsin Alzheimer's Disease Research Center Clinical Core, or other studies affiliated with the UW Alzheimer's Research Program.

Disclose amyloid, tau results

Intervention Type OTHER

Release of results from investigational agents conducted under IND 107114, IND 166860, and IND 134516

Follow-up Assessments

Intervention Type OTHER

self-report psychosocial and behavioral questionnaires

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Disclose amyloid, tau results

Release of results from investigational agents conducted under IND 107114, IND 166860, and IND 134516

Intervention Type OTHER

Follow-up Assessments

self-report psychosocial and behavioral questionnaires

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing to provide informed consent.
* Willing to comply with all study procedures and be available for the duration of the study.
* Individuals at least 50 years of age.
* Enrolled in Wisconsin Registry for Alzheimer's Prevention (WRAP) or Alzheimer's Disease Research Center Clinical Core (ADRC)
* Previously adjudicated as cognitively unimpaired having mild cognitive impairment (MCI), or impaired but do not meet diagnostic criteria for mild cognitive impairment or dementia (classified as "Impaired-Not MCI" by the WRAP and ADRC cohorts) at their last WRAP or ADRC study visit at the time of enrollment into this study
* Have completed or able to complete amyloid and/or tau PET scans as part of a UW Alzheimer's Research Study

Exclusion Criteria

* Diagnosis of dementia at the time of enrollment as determined by the most recent parent WRAP/ADRC study visit diagnostic consensus conference using standard NIA-AA 2011 diagnostic criteria. Participants who develop dementia after enrolling into this study may remain enrolled if they maintain decisional capacity and are able to follow study instructions and procedures.
* Individuals who lack decisional capacity to provide informed consent as determined by significant difficulty in understanding materials and information about study procedures during recruitment and/or informed consent discussions.
* Not suitable for study participation due to other reasons at the discretion of the investigators.

Minimum Eligible Age

50 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes